Table 3.
Model Output for Medication DCE
| Class Proportions | Symbol | Class 1 | Class 2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 0.394 | 0.606 | ||||||||
| Utility Parameters | Parameter | SE | T-Ratio | Parameter | SE | T-Ratio | |||
| Treatment mode constants | |||||||||
| Oral |  |
−0.829 | 0.508 | −1.630 | 1.376 | * | 0.331 | 4.160 | |
| Nasal spray |  |
−2.755 | * | 1.028 | −2.680 | 0.555 | 0.298 | 1.860 | |
| Infusion |  |
−1.573 | * | 0.546 | −2.880 | 1.006 | * | 0.280 | 3.590 |
| (Reference category: Current treatment) | |||||||||
| Effectiveness | |||||||||
| Oral | |||||||||
| 30% improvement |  |
0.830 | 0.494 | 1.680 | 0.556 | 0.318 | 1.750 | ||
| 50% improvement |  |
2.019 | * | 0.500 | 4.040 | 0.959 | * | 0.324 | 2.960 |
| 70% improvement |  |
1.911 | * | 0.51 | 3.750 | 1.238 | * | 0.343 | 3.610 |
| (Reference category: 10%) | |||||||||
| Nasal spray | |||||||||
| 30% improvement |  |
0.869 | 1.202 | 0.720 | 1.009 | * | 0.355 | 2.840 | |
| 50% improvement |  |
2.489 | * | 1.110 | 2.240 | 1.343 | * | 0.338 | 3.970 |
| 70% improvement |  |
3.407 | * | 1.139 | 2.990 | 1.833 | * | 0.345 | 5.310 |
| (Reference category: 10%) | |||||||||
| Infusion | |||||||||
| 30% improvement |  |
0.443 | 0.714 | 0.620 | 0.064 | 0.342 | 0.190 | ||
| 50% improvement |  |
0.317 | 0.838 | 0.380 | 0.934 | * | 0.342 | 2.730 | |
| 70% improvement |  |
2.173 | * | 0.737 | 2.950 | 1.092 | * | 0.338 | 3.230 |
| (Reference category: 10%) | |||||||||
| Remission | |||||||||
| Oral | |||||||||
| 10% |  |
0 | Fixed parameter | 0 | Fixed parameter | ||||
| 30% |  |
0 | Fixed parameter | 0 | Fixed parameter | ||||
| 50% |  |
−0.146 | 0.382 | −0.380 | 0.464 | 0.280 | 1.660 | ||
| (Reference category: 0%) | |||||||||
| Nasal spray | |||||||||
| 30% |  |
0 | Fixed parameter | 0 | Fixed parameter | ||||
| 50% |  |
0 | Fixed parameter | 0 | Fixed parameter | ||||
| (Reference category: 10%) | |||||||||
| Infusion | |||||||||
| 30% |  |
0 | Fixed parameter | 0 | Fixed parameter | ||||
| 50% |  |
0 | Fixed parameter | 0 | Fixed parameter | ||||
| (Reference category: 10%) | |||||||||
| Risk of weight gain | |||||||||
| Oral | |||||||||
| 5% risk |  |
0.683 | * | 0.338 | 2.020 | 0.047 | 0.250 | 0.190 | |
| (Reference category: 10–15% risk) | |||||||||
| Monthly out of pocket cost | |||||||||
| Oral | |||||||||
| $120-$160 |  |
−1.548 | * | 0.466 | −3.320 | −0.125 | 0.327 | −0.380 | |
| $200-$240 |  |
−1.495 | * | 0.486 | −3.080 | −0.337 | 0.322 | −1.050 | |
| $280-$320 |  |
−1.719 | * | 0.456 | −3.770 | −0.367 | 0.321 | −1.140 | |
| (Reference category: $40-$80) | |||||||||
| Nasal spray and Infusion (Class 1) | |||||||||
| $500 |  |
−1.976 | * | 0.563 | −3.510 | - | - | - | |
| $750 |  |
−3.131 | * | 1.077 | −2.910 | - | - | - | |
| $1000-$2500 |  |
−3.950 | * | 0.677 | −5.840 | - | - | - | |
| (Reference category: $100-$250) | |||||||||
| Nasal spray and Infusion (Class 2) | |||||||||
| $1500 |  |
- | - | - | −0.711 | * | 0.204 | −3.490 | |
| $2000 |  |
- | - | - | −1.004 | * | 0.288 | −3.490 | |
| $2500 |  |
- | - | - | −1.358 | * | 0.303 | −4.480 | |
| (Reference category: $100-$1000) | |||||||||
Notes: *Statistically significant at the 5%-level. Restricted log-likelihood: −1353.023; Log-likelihood: −759.434; McFadden Pseudo R-squared: 0.439; Number of respondents: 61; Number of choice observations: 976. All categorical attributes were dummy coded and should be compared to the reference category. Omitted attributes: frequency of administration, onset of response, risk of dissociation (nasal spray and infusion only), ability to drive the next day (nasal spray and infusion only), risk of blood pressure increase (nasal spray and infusion only), risk of sleepiness or drowsiness (oral only) and risk of headache, dizziness or nausea (oral only).